Publications in collaboration with researchers from Hammersmith Hospital (6)

2022

  1. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Leukemia, Vol. 36, Núm. 7, pp. 1825-1833

2020

  1. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors

    Leukemia, Vol. 34, Núm. 6, pp. 1495-1502

2019

  1. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

    Journal of Cancer Research and Clinical Oncology, Vol. 145, Núm. 6, pp. 1589-1599

  2. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2018

  1. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial

    Journal of Clinical Oncology, Vol. 36, Núm. 3, pp. 231-237

2016

  1. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

    Leukemia, Vol. 30, Núm. 8, pp. 1648-1671